What is the treatment for a male patient with green discharge and dysuria (painful urination) post-coitus, with a negative sexually transmitted infection (STI) test result?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Green Discharge and Post-Coital Dysuria with Negative STI Testing

Despite negative STI testing, this patient should be treated empirically for nongonococcal urethritis (NGU) with doxycycline 100 mg orally twice daily for 7 days, as the most common causes of NGU (Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, and Trichomonas vaginalis) may not be detected by standard STI panels. 1

Clinical Context and Diagnostic Considerations

The presentation of green discharge with burning after intercourse is consistent with urethritis, even when initial STI tests are negative. 1, 2

Key diagnostic points:

  • Urethritis is confirmed by mucopurulent/purulent discharge, ≥5 white blood cells per oil immersion field on urethral Gram stain, or ≥10 white blood cells per high-power field in first-void urine 1, 2
  • C. trachomatis causes only 23-55% of NGU cases, with the proportion declining over time 1
  • Ureaplasma urealyticum accounts for 20-40% of NGU cases, and Trichomonas vaginalis causes 2-5% 1
  • The etiology of many NGU cases remains unknown even with comprehensive testing 1

Treatment Algorithm

First-Line Treatment

Doxycycline 100 mg orally twice daily for 7 days 1, 2, 3

This regimen provides coverage for:

  • Chlamydia trachomatis (if missed by initial testing) 2, 4
  • Ureaplasma urealyticum 1
  • Mycoplasma genitalium (partial coverage) 2, 3

Alternative Regimens (if doxycycline contraindicated)

  • Erythromycin base 500 mg orally 4 times daily for 7 days, OR 1
  • Erythromycin ethylsuccinate 800 mg orally 4 times daily for 7 days 1

For patients intolerant of high-dose erythromycin:

  • Erythromycin base 250 mg orally 4 times daily for 14 days, OR 1
  • Erythromycin ethylsuccinate 400 mg orally 4 times daily for 14 days 1

Management of Persistent or Recurrent Symptoms

If symptoms persist or recur after completing initial therapy: 1

  1. First, assess compliance and re-exposure:

    • Re-treat with initial regimen if poor compliance or re-exposure to untreated partner 1
  2. If compliance was adequate and no re-exposure:

    • Perform wet mount examination and culture of intraurethral swab for Trichomonas vaginalis 1
    • If T. vaginalis is positive, treat with metronidazole 2 g orally as single dose 1, 3
    • If T. vaginalis is negative, re-treat with extended alternative regimen (erythromycin base 500 mg orally 4 times daily for 14 days) to cover possible tetracycline-resistant U. urealyticum 1

Partner Management

Sexual partners must be evaluated and treated: 1

  • Partners with last sexual contact within 30 days of symptom onset should be evaluated and treated 1
  • If the patient is asymptomatic, partners with contact within 60 days of diagnosis should be evaluated and treated 1, 5
  • Patient should abstain from sexual intercourse until both patient and partners complete therapy and are symptom-free 1, 2

Important Caveats and Pitfalls

Common pitfalls to avoid:

  • Do not rely solely on negative STI testing to exclude urethritis—many causative organisms are not detected by standard panels 1, 5
  • Specific diagnostic tests for U. urealyticum are not routinely indicated and would not alter initial therapy 5
  • Do not re-treat based on symptoms alone without documenting objective signs of urethral inflammation (discharge or elevated WBC count) 1
  • Ensure partner treatment to prevent reinfection—this is a leading cause of treatment failure 1, 6

For persistent symptoms after doxycycline and erythromycin:

  • Reassure the patient that persistent NGU does not cause known complications and is not necessarily sexually transmitted 1
  • However, re-evaluate if exposed to new sexual partner 1
  • Urologic examination rarely reveals specific etiology in these cases 1

Follow-Up Recommendations

  • Return for evaluation only if symptoms persist or recur after completing therapy 1
  • Failure to improve within 3 days of starting treatment requires re-evaluation of diagnosis and therapy 1
  • Repeat testing for STIs should occur at 3 months after treatment 2
  • Avoid repeat testing less than 3 weeks after treatment due to risk of false-positive results 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Urethritis: Rapid Evidence Review.

American family physician, 2021

Guideline

Ureaplasma Urealyticum Testing and Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Leukorrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.